2016 American Transplant Congress
Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.
Introduction: Cancer is one of the major causes of death in kidney transplantation. Despite more mortality in colon cancer (CRC), similar incidence than general population…2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.
Liver Science Department, King's College London, London, United Kingdom.
CD4+CD25+FOXP3+ regulatory T cells (Tregs) have an essential role in immune regulation and constitute a key target for cellular immunotherapies in transplantation. IL-2 is critical…2016 American Transplant Congress
The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.
Purpose: Evidence points towards activation of the mineralocorticoid receptor (MR) to be involved in CNI nephrotoxicity. The SPIREN trial was designed to test the hypothesis…2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Frequencies of CD4+25hiFoxp3+ T Cells in Long-Term Follow-Up of Sirolimus-Converted Kidney Transplant Recipients
Background: Tacrolimus(TAC) and Sirolimus(SRL) are commonly used immunosuppressive drugs in kidney transplantation. SRL has been shown to induce the expansion of regulatory T cells in…2015 American Transplant Congress
NK Cells of Kidney Transplant Recipients Show a Reduced Capacity to Produce Cytokines But Retain Their Cytotoxic Capacity
The role of NK cells in either graft rejection or tolerance induction is still discussed controversially. In order to clarify the effect of long-term immunosuppression…